Skip to main content

Cell Division Control and Treatment

Guest Editor:
Jiří Kohoutek, PhD, Masaryk University, Czech Republic

Submission Status: Open   |   Submission Deadline: 30 June 2024

Cell Division is calling for submissions to our Collection on "Cell Division Control and Treatment". This Collection will discuss how the dysregulated progression of the cell cycle can contribute to cancer onset, development and resistance, and can be exploited to improve patient treatment.

Image Credit: arinarici / Getty Images / iStock

About the collection

The cell cycle is a very complex and precisely controlled cellular process. It is not a surprise that transition between particular phases of the cell cycle as well as control mechanisms overseeing proper progress through the cell cycle must be embedded. Cyclin-dependent kinases with their specific cyclins carry out the transition between particular cell cycle phases.  Dysregulation of their function may drive cell transformation and carcinogenesis by signaling a deregulated cell cycle, and chromosome instability. At the same time, the dependence of cancer cells on more functional drivers or corrupted repressors of the cell cycle causes increased vulnerability of cancer cells to diverse treatments by specific inhibitors. Nevertheless, resistance to chemotherapy or radiotherapy commonly develops during cancer treatment.  Thus, the identification of new synthetic lethal combinations of drugs or genetic defects, and suitable biomarkers are critically needed for the exploitation of novel regimens to provide patients with more effective treatment management. 

Thus, this Collection will discuss how the dysregulated progression of the cell cycle can contribute to cancer onset, development and resistance, and can be exploited to improve patient treatment.

  1. This review aims to outline mitotic kinase inhibitors’ roles as potential therapeutic targets and assess their suitability as a stand-alone clinical therapy or in combination with standard treatments for advan...

    Authors: Alexandra N. Aquino-Acevedo, Joel A. Orengo-Orengo, Melanie E. Cruz-Robles and Harold I. Saavedra
    Citation: Cell Division 2024 19:21
  2. CIP/KIP and INK4 families of Cyclin-dependent kinase inhibitors (CKIs) are well-established cell cycle regulatory proteins whose canonical function is binding to Cyclin-CDK complexes and altering their functio...

    Authors: Lucia Csergeová, David Krbušek and Radoslav Janoštiak
    Citation: Cell Division 2024 19:11
  3. Because of the progress on the diagnosis and treatment for patients with breast cancer (BC), the overall survival of the patients has been improved. However, a number of BC patients cannot benefit from the exi...

    Authors: Zhaoyang Jia, Feng Wang, Gongzhuo Li, Ping Jiang, Yuanxiu Leng, Longzhu Ke, Li Luo and Wei Gao
    Citation: Cell Division 2024 19:8
  4. Growth differentiation factor 15 (GDF15), a member of the transforming growth factor beta (TGF-β) superfamily, is involved in various pathophysiological processes such as anorexia, obesity, inflammation, and t...

    Authors: Dongliang Yang, Zhongyin He, Jiawei Lu, Xiaolin Yuan, Haiyong Liu, Yagang Xue, Ting Chen and Hongxing Gu
    Citation: Cell Division 2023 18:21
  5. Chemotherapy resistance is a leading cause of treatment failure in cases of cervical adenocarcinoma (ADC), and no effective treatment approach has yet been found. We previously identified the differentially ex...

    Authors: Jun-wen Zhang, Ya-nan Wang, Mei-ling Zhong and Mei-rong Liang
    Citation: Cell Division 2023 18:15

Submission Guidelines

Back to top

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Cell Division Control and Treatment" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.